PF-Atlas › Clinical Trials › NCT03208933

Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis .

Pirfenidone · Phase 3

Registry ID
NCT03208933
Phase
Phase 3
Status
Completed
Drug / intervention
Pirfenidone
Sponsor
Hoffmann-La Roche
Start
2017-10-23
Enrollment
60
Locations
11

About this trial

This study is a national, multicenter, interventional, non-randomized, non-controlled, open-label study to assess the effectiveness of pirfenidone in participants with IPF in Russian clinical practice.

View NCT03208933 on ClinicalTrials.gov →

Explore related

All Pirfenidone trialsAll IPF trials

Related trials

Pirfenidone — NCT00001959pirfenidone — NCT00662038Pirfenidone — NCT02951429Pirfenidone — NCT00287729Pirfenidone — NCT01504334Pirfenidone — NCT02932566
Medical disclaimer. This page summarizes public trial data for NCT03208933 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.